Nerve Growth Factor
Also known as: Beta-NGF, beta‑NGF, Cenegermin, Nerve Growth Factor, NGF, NGF-beta, Oxervate, rhNGF
Source Nerve Growth Factor at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Nerve Growth Factor (NGF) is a neurotrophin that supports survival and regeneration of sensory neurons. Recombinant human NGF (cenegermin) is approved as a topical eye‑drop (Oxervate) for neurotrophic keratopathy, a condition with non‑healing corneal ulcers. Research also explores NGF inhibition for chronic pain and indirect strategies that raise NGF levels for neuroprotection, but these uses remain investigational.
Mechanism of Action
NGF binds the high‑affinity tropomyosin‑related kinase A (TrkA) receptor on sensory and epithelial cells, activating intracellular pathways (PI3K/Akt, MAPK) that promote cell survival, proliferation, and axonal growth. In the cornea, this signaling enhances epithelial cell migration and nerve regeneration, accelerating wound closure. Conversely, monoclonal antibodies that block NGF‑TrkA signaling reduce nociceptive signaling, offering a potential analgesic effect.
What the Research Shows
A pivotal multicenter, double‑masked trial of 48 patients with neurotrophic keratopathy showed that 69.6% of eyes receiving cenegermin healed versus 29.2% with vehicle after eight weeks, with significant reductions in lesion size and disease progression. The drug was well tolerated, with only mild, transient ocular irritation reported. In veterinary medicine, species‑specific anti‑NGF antibodies have demonstrated analgesic efficacy in early canine and feline osteoarthritis trials, though human antibodies are not yet approved. Systemic NGF inhibition (fulranumab) is under investigation for post‑herpetic neuralgia. Indirect evidence from probiotic and Hericium erinaceus studies suggests that increasing endogenous NGF may improve neuroinflammation and mood, but these findings are preliminary and not based on NGF administration.
Reported Benefits
Topical cenegermin provides a clinically proven option to promote corneal epithelial healing in patients with neurotrophic keratopathy, reducing lesion size and preventing progression. Anti‑NGF antibodies show promise for reducing chronic joint pain in dogs and cats, indicating a potential analgesic pathway. Emerging data suggest that raising NGF levels could support neuronal health and modulate mood, offering a theoretical neuroprotective benefit.
Limitations of the Evidence
Approved use is limited to ocular application; systemic or long‑term NGF therapy lacks robust clinical data. Anti‑NGF antibodies remain investigational for human pain, with safety and efficacy still under evaluation. Studies linking NGF to mood or neuroprotection rely on indirect measures (probiotic‑induced metabolites or mushroom extracts) and involve small sample sizes, limiting generalisability. The evidence base for non‑ocular indications is therefore insufficient for clinical recommendation.
Safety Considerations
Topical cenegermin was associated mainly with mild, transient ocular adverse events such as irritation or redness; no serious systemic effects were reported in the pivotal trial. Systemic NGF administration has not been widely studied in humans, so safety remains uncertain. Anti‑NGF monoclonal antibodies in veterinary trials were well tolerated, but human safety data are pending. Caution is advised against off‑label systemic use until further research confirms safety.
How It Is Administered
The approved formulation (cenegermin, 20 µg/mL) is administered as eye drops six times daily for eight weeks. Other routes—intravitreal, subcutaneous, or intravenous—are mentioned in the product profile but are investigational and not approved. Anti‑NGF antibodies used in animal studies are delivered by injection; human formulations are still in clinical development.
Routes of Administration
Goals & Uses
- Neuroprotection in Alzheimer's diseaseNeurologyLow
- Dry eye diseaseOphthalmologyModerate
- Wound healing / corneal regenerationOphthalmology / DermatologyModerate
- NeuroprotectionNeurologyModerate
- Peripheral neuropathy treatmentNeurologyLow
- Treatment of neurotrophic keratitisOphthalmologyHigh
- NeuroregenerationFunctional RecoveryModerate
Contraindications
- Active malignancyOncologyHighUse caution or avoid depending on agent and context
- Hypersensitivity to NGF or formulation componentsAllergyHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Known hypersensitivity to recombinant NGF productAllergyHigh
- Active ocular infectionOphthalmologyHigh
Adverse Effects
- Systemic hyperalgesia / myalgiaNeurological / MusculoskeletalCommon
- Hypersensitivity reactionsImmunologicRare
- Ocular hyperemiaOphthalmologicCommon
- Injection site painLocalCommonPain at the injection site
- Corneal deposits (topical)OphthalmologicUncommon
- Flu‑like syndromeSystemicUncommon
- Eye pain / foreign body sensationOphthalmologicCommon
Drug Interactions
- Anti-NGF antibodies (tanezumab, fasinumab)High
- NSAIDs / AnalgesicsModerate
- Other neurotrophic agents (e.g., BDNF mimetics)Moderate
- Immunosuppressants (e.g., cyclosporine)Low
- Corticosteroids (topical ocular)Moderate
Population Constraints
- Pediatric patientsAgeRelative
- Patients with chronic pain conditionsComorbidityRelative
- Immunocompromised patientsImmunologicRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trial authorization required; not marketed.
- United StatesInvestigationalInvestigational New Drug (IND) applications for Alzheimer's and ocular surface disease.
- United KingdomInvestigationalSubject to MHRA clinical trial approval only.
Not approved for any indication in major jurisdictions; used under clinical trial protocols or compassionate use programs.
Evidence & Sources
- Journal ArticleModeratePflugfelder SC, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleModerateEnomoto M, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleModerateLevi-Montalcini R, Angeletti PU1968-01-01T00:00:00.000000Z
- Journal ArticleHighHuerta MÁ, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateKim CS, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateNagano M, et al.2010-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition is cenegermin approved to treat?
Cenegermin (Oxervate) is approved as a topical eye‑drop for neurotrophic keratopathy, a disease characterized by persistent corneal epithelial defects and reduced corneal sensitivity.
How does NGF promote corneal healing?
NGF activates TrkA receptors on corneal epithelial cells and sensory nerves, stimulating cell proliferation, migration, and nerve regeneration. This accelerates closure of epithelial defects and restores corneal integrity.
Are anti‑NGF antibodies available for human pain management?
No anti‑NGF monoclonal antibodies are currently approved for human use. They are under investigation in clinical trials for conditions such as post‑herpetic neuralgia, but safety and efficacy data are still emerging.
Can NGF be used to treat depression or enhance brain function?
Direct NGF therapy for mood disorders has not been demonstrated. Indirect approaches—like probiotic‑induced metabolites or mushroom extracts that raise endogenous NGF—show modest effects in small studies, but evidence is preliminary.
What side effects might occur with topical NGF eye drops?
The main reported adverse events are mild, transient ocular irritation, redness, or discomfort. No serious systemic adverse effects were observed in the pivotal trial, but patients should be monitored for local reactions.
What is Nerve Growth Factor?
Nerve Growth Factor (NGF) is a neurotrophin that supports survival and regeneration of sensory neurons. Recombinant human NGF (cenegermin) is approved as a topical eye‑drop (Oxervate) for neurotrophic keratopathy, a condition with non‑healing corneal ulcers. Research also explores NGF inhibition for chronic pain and indirect strategies that raise NGF levels for neuroprotection, but these uses remain investigational.
What is Nerve Growth Factor used for?
Nerve Growth Factor is educationally associated with: Neuroprotection in Alzheimer's disease, Dry eye disease, Wound healing / corneal regeneration, Neuroprotection, Peripheral neuropathy treatment, Treatment of neurotrophic keratitis, Neuroregeneration. Educational only — not medical advice.
How is Nerve Growth Factor administered?
Recorded routes of administration: Intranasal, Intravenous, Intravitreal, Subcutaneous, Topical, Topical Ocular.
What are the potential side effects of Nerve Growth Factor?
Reported adverse effects include: Systemic hyperalgesia / myalgia, Hypersensitivity reactions, Ocular hyperemia, Injection site pain, Corneal deposits (topical), Flu‑like syndrome, Eye pain / foreign body sensation. This list is not exhaustive — consult a qualified clinician.
Who should avoid Nerve Growth Factor?
Recorded contraindications: Active malignancy, Hypersensitivity to NGF or formulation components, Pregnancy, Known hypersensitivity to recombinant NGF product, Active ocular infection. Consult a qualified clinician before use.